Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

83.89 +0.84 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,200,522
Open 83.37
Bid (Size) 83.96 (1)
Ask (Size) 84.10 (1)
Prev. Close 83.05
Today's Range 82.76 - 84.52
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 3.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These two stocks have had their issues in recent years, but both look like reliable long-term bets. 
Via The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga

Performance

YTD
+0.78%
+0.78%
1 Month
+12.68%
+12.68%
3 Month
+32.84%
+32.84%
6 Month
+14.28%
+14.28%
1 Year
+10.94%
+10.94%

More News

Read More
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Why Gilead Sciences Stock Thrashed the Market Today
Via The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Via Benzinga
What the Options Market Tells Us About Gilead Sciences
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Unveiling 10 Analyst Insights On Gilead Sciences
Via Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
Biotech Breakout: Stocks for Your Watchlist
Via MarketBeat
Topics ETFs
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
Four Stocks To Watch This Week - Monday, Sept 9
Via Talk Markets
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Via Investor's Business Daily
Exposures Product Safety
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.